Table 4. Clinical outcomes during the 5-year follow-up.
| Death | Control | p | |
|---|---|---|---|
| (N=162) | (N=162) | ||
| Delayed graft function, n (%) | 67 (41) | 47 (29) | 0.012 |
| Treatment for acute rejection, n (%) | 62 (38) | 47 (29) | 0.078 |
| All acute rejection treated with r-ATG, n (%) | 22 | 11 | |
| eGRF, mean ± DP (n) | |||
| Day 1 | 12.3 ± 11.6 (161) | 13.3 ± 12.1 (162) | 0.307 |
| Month 3 | 50.8 ± 25.1 (118) | 56.7 ± 20.7 (157) | 0.137 |
| Month 6 | 50.8 ± 21.6 (102) | 58.4 ± 20.8 (154) | 0.839 |
| Month 12 | 55.8 ± 25.3 (91) | 61.4 ± 20.4 (148) | 0.1 |
| Month 24 | 49.9 ± 21.9 (67) | 59.8 ± 20.5 (148) | 0.669 |
| Month 36 | 50.3 ± 23.8 (43) | 60.2 ± 20.3 (141) | 0.162 |
| Month 48 | 45.9 ± 23.8 (20) | 58.5 ± 20.2 (137) | 0.368 |
| Month 60 | - | 58.1 ± 21.3 (137) |
r-ATG: rabbit anti-thymocyte globulin; eGRF: estimated glomerular filtration rate using the modification of diet in renal disease formula (mL/min/1.73 m2).